Slide 1: Orion Interim Report 1−3/2020
Orion Interim Report 1−3/2020
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-March 2020
Highlights in January-March 2020
Slide 4: COVID-19 increased demand and challenges
COVID-19 increased demand and challenges 1 Net sales grew clearly due to strongly increased demand of medicines caused by the COVID-19 pandemia. 3 Darolutamide received marketing authorisations in Japan and the EU. The growth was partly due to hoarding and inventory increases, partly due to 4 increa
Slide 5: COVID-19 pandemia impacts on Orion
COVID-19 pandemia impacts on Orion The most important thing is to take care of the health and safety of employees, the continuity of production and patient safety in ongoing clinical trials. Strong demand spike of generic prescription The global supply chains of pharmaceuticals drugs and OTC product
Slide 6: Key figures 1−3/2020
Key figures 1−3/2020 Net sales Operating profit Operating profit Cash flow per share margin before financial items 280 84 30% 0.34 MEUR (241) MEUR (55) (23%) EUR (0.40) +16% +53% -15% Interim Report 1-3/2020 © Orion Corporation 28 April 2020 6
Slide 7: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 11 -6.6 -0.7 2.3 -3.6 84 22 -1 280 27 2 8 7 9 55 241 -6 -2 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and prod
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-3/2020 MEUR 1-3/2020 1-3/2019 13% 100 +5% +13% 30% 90 8% 80 84 87 83 70 74 +16% 60 50 +37% 51 40 44 +56% 30 36 31% 18% 20 26 22 10 14 Finland Scandinavia 0 Other Europe North America ROW Interim Report 1-3/2020 © Orion Corporation 28 April 2020 8
Slide 9: Proprietary and Specialty Products showed strong growth
Proprietary and Specialty Products showed strong growth 1−3/2020 1−3/2019 1-3/2020 MEUR +21% 160 5% 135 +24% 140 8% 120 111 111 100 89 39% 80 +12% -18% 60 48 % 40 23 21 15 18 20 0 Proprietary Products Specialty Proprietary Animal Fermion and Specialty Products Products Products Health Contract Manuf
Slide 10: Best-selling pharmaceuticals 1−3/2020
Best-selling pharmaceuticals 1−3/2020 Net sales Change vs. . Indication EUR million 1−3/2019 1. Asthma, COPD 35 +33% 2. Parkinson’s disease 28 +33% 3. Acute heart failure 19 +17% 4. Intensive care sedative 17 -14% 5. Animal sedatives 9 -8% 6. Inflammatory pain 8 +37% 7. Divina-sarja Menopausal sympt
Slide 11: Proprietary Products
Proprietary Products
Slide 12: Strong growth - Dexdor® declined clearly less than expected
Strong growth - Dexdor® declined clearly less than expected Proprietary Products MEUR +33% sales split 1-3/2019 40 +33% 35 12% 35 25% 30 28 +17% -14% 26 25 21 19 19 20 17 17 17% 15 10 5 15% 31% 0 Easyhaler® Parkinson's Simdax® Dexdor® Parkinson's Easyhaler® franchise franchise Dexdor® Simdax® 1−3/20
Slide 13: Easyhaler® sales +33%
Easyhaler® sales +33% 1-3/2020 Budesonide-formoterol Easyhaler® MEUR 20 (15) +31% 40 1-3/2020 Other Easyhaler® products MEUR 14 (11) +36% 30 Sales, MEUR 20 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2015 2016 2017 2018 2019 20 Other Budesonide-formoterol Easyhaler® Interim R
Slide 14: Parkinson's franchise sales +33%
Parkinson’s franchise sales +33% 1-3/2020 Own sales MEUR 13 (8) +65% 50 45 1-3/2020 Deliveries to partners MEUR 15 (13) +14% 40 35 Sales, MEUR 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2015 2016 2017 2018 2019 20 Orion own sales Deliveries to partners Interim
Slide 15: Dexdor® and Simdax®
Dexdor® and Simdax® 1-3/2020 Dexdor® MEUR 17 (19) -14 % 1-3/2020 Simdax® MEUR 19 (17) +17 % 20 20 15 15 10 10 5 5 0 0 Q1 Q1 2015 2016 2017 2018 2019 20 2015 2016 2017 2018 2019 20 Interim Report 1-3/2020 © Orion Corporation 28 April 2020 15
Slide 16: Specialty Products
Specialty Products
Slide 17: Specialty Products: COVID-19 clearly increased demand
Specialty Products: COVID-19 clearly increased demand Development of net sales Net sales by region Net sales by products 1−3/2020 1−3/2020 MEUR +14% 4% 80 74 10% 70 65 15% 27% 60 50 +19% +51% 40 55% 30 26 22 21 20 14 20% 69% 10 0 Finland Scandinavia Eastern Finland Generic drugs Europe & Scandinavia
Slide 18: In Finland, market of reference priced prescription drugs turned to growth
In Finland, market of reference priced prescription drugs turned to growth due to strong demand in March The market of reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1−3/2020) in Finland MEUR 110 (102) MEUR 30 (27) Market development Orionin’
Slide 19: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−3/2020 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 750 million prescription Orion market share in MEUR drugs pharmacy 90 86 Orion market share in 80 70 30 pharm
Slide 20: Research and development
Research and development
Slide 21: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (nmCRPC) I II III Registration 3) Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (ta
Slide 22: Orion's key business targets in 2020
Orion's key business targets in 2020 • Marketing authorisation received in Commercialisation of darolutamide in Japan and EU for the treatment of Europe. ARASENS trial (metastatic prostate non-metastatic castration-resistant 1. cancer) continues in order to expand the prostate cancer. indication for
Slide 23: Orion's key business targets in 2020
Orion's key business targets in 2020 Strengthening Orion’s position as the most • Orion grew faster than the significant provider of generic drugs in market and is a clear market 3. Finland. Competitive product portfolio in leader both in self-care Specialty Products and strengthening of products an
Slide 24: Patient safety and reliable supply of medications are priorities during COVID-19
Patient safety and reliable supply of medications are priorities also during COVID-19 pandemic MATERIAL THEMES OF SUSTAINABILITY Ensuring patient safety and reliable supply of Responsibility for the environment, employees medications and the ethics and transparency of operations • Ensuring reliable
Slide 25: Outlook
Outlook
Slide 26: Outlook for 2020
Outlook for 2020 (provided on 24 April 2020) Net sales Orion estimates that in 2020 net sales will be at a similar level as in 2019 (net sales in 2019 were EUR 1,051 million). Operating profit Operating profit is estimated to be at a similar level as in 2019 (in 2019 operating profit was EUR 253 mil
Slide 27: Orion calendar
Orion calendar Annual General Meeting 6/5/2020 Half-Year Report 1-6/2020 17/7/2020 Interim Report 1-9/2020 21/10/2020
Slide 28: Building well-being
Building well-being